Form D · Biotechnology
Phythera Therapeutics Inc.
Irvine, CA · CIK 0002017198
Offering snapshot reported May 16, 2024 · SEC filing
- Reported sold
- $468 Offering amount: $468
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 17, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 16, 2024 | Initial | $468 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-513537
Source: Form D, filed May 16, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Charles S. Irving, Ph.D. | Director, Executive, Promoter |
| Zamira Nazirova Nasonkin | Promoter |
| Igor O. Nasonkin, Ph.D. | Director, Executive, Promoter |
| Judith Segall | Director, Executive, Promoter |
| Hal Sternberg, Ph.D. | Director, Executive, Promoter |
| Ngoc T. Tran | Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
103 Rockview
Irvine, CA, 92612
Irvine, CA, 92612